Extracorporeal shockwave therapy for patellar tendinopathy: a review of the literature

M T van Leeuwen, J Zwerver, I van den Akker-Scheek

ABSTRACT
Background and purpose: Extracorporeal shockwave therapy (ESWT) has become a popular treatment for patellar tendinopathy. The purpose of this review was to study the effectiveness of ESWT treatment for patellar tendinopathy; to draft guidelines for an effective treatment protocol of ESWT treatment; and to identify topics for further research.

Methods: A computerised search of the Medline and Embase databases was conducted on 1 August 2007, to identify studies dealing with the effectiveness of ESWT for patellar tendinopathy.

Results: Seven articles describing the effectiveness of ESWT on patellar tendinopathy, all published after 2000, were included. These studies included a total of 283 patients (298 tendons), 204 of whom (215 tendons) were assigned to ESWT treatment. The treatment results were positive but most studies had methodological deficiencies, small numbers and/or short follow-up periods. Method of application and shockwave generation, energy level, number and frequency of treatments, use of (local) anaesthesia and method of localisation were variable.

Conclusion: ESWT seems to be a safe and promising treatment for patellar tendinopathy with a positive effect on pain and function. Based on current knowledge it is impossible to recommend a specific treatment protocol. Further basic and clinical research into the working mechanism and effectiveness of ESWT for patellar tendinopathy are necessary.

Patellar tendinopathy, also called jumper’s knee, is a chronic overuse injury of the patellar tendon causing pain at the inferior pole of the patella. The prevalence is particularly high in athletes. Among elite volleyball and basketball players a prevalence over 40% has been described. Because of its chronicity and a lack of consensus about which treatment is the most adequate, patellar tendinopathy has a major impact on the career of many athletes and for some it is the reason to end their career prematurely.

The aetiology of patellar tendinopathy is not completely understood, but repetitive overload is thought to be an important factor. Histopathological examinations of affected patellar tendons revealed the absence of inflammatory cells and no increased levels of prostaglandin. Consequently, the former term tendinitis should be replaced by tendinosis, which reflects the underlying process of tendon degeneration and the failed healing response. The term tendinopathy is now often used clinically.

Based on the present literature it is not possible to decide what is the most appropriate and effective treatment for patellar tendinopathy.
Results

We found seven articles in which the effectiveness of ESWT on patellar tendinopathy was described, all published after 2000. These studies included a total of 283 patients (298 tendons), 204 of whom (215 tendons) were assigned to ESWT treatment. The main study characteristics are presented in table 2.

Description of the studies

In 2000 Vara et al studied the effectiveness of different ESWT energy levels for patellar tendinopathy in 27 patients. In this prospective, randomised, single-blind trial, one group received from one to five treatments with an energy level of 0.105–0.437 mJ/mm². Another group (placebo) received one treatment with an energy level of 0.04 mJ/mm². Evaluation 2 years after the last treatment showed an improvement of 61% in the study group for VAS score, pressure pain and functional improvement. In the placebo group there was 7.5% improvement, and 74% and 15% of the patients in the study group and placebo group, respectively, thought the results were good or satisfactory. A limitation of this study was that it was not a double-blind trial, so patients knew whether they received placebo treatment or real treatment. This study showed good results in favour of the group that received ESWT treatment with an energy level of 0.105–0.437 mJ/mm², but the results could be biased, as a single-blind protocol was used.

In a non-randomised, prospective pilot study in 2002 by Lohrer et al the effectiveness of radial shockwave therapy (R SWT) on patellar tendinopathy was evaluated in 45 patients who had not responded successfully to previous conservative treatments. Treatment consisted of three to five RSWT sessions with an energy level from 0.06 to 0.18 mJ/mm². Pain at rest, pain during exercise, pressure pain (all VAS score) and pain-free running time (min) were evaluated after 1, 4, 12, 26 and 52 weeks. During 1 year all scores improved significantly. One year after the last treatment 40% of the patients with patellar tendinopathy were pain-free, 24.4% had improved, and 36.5% of the patients showed no improvement. Although Lohrer et al did not include a control group for comparison purposes, they concluded that ESWT does have a therapeutic effect on patellar tendinopathy.

In 2003 Peers et al retrospectively compared results of surgical treatment with ESWT for patellar tendinopathy in 27 patients (28 tendons). None of the patients had shown improvement after previous conservative treatment. After three ESWT sessions of 0.08 mJ/mm² in 14 patients (15 knees) and after tenotomy of the patellar tendon with resection of degenerative tissue in 13 patients, VAS and VISA scores, Roles & Maudsley (R&M) classification, length of the rehabilitation period and absence from work were evaluated. Two years after treatment no significant difference in VAS and VISA scores or R&M classification was found, but the surgical treatment group did have a longer absence from work period postsurgically. A limitation of this study was lack of randomisation, so a selection bias may have possibly influenced the results. For patients it is difficult to choose between surgery and undergoing ESWT. The risk of complications, intensive postoperative rehabilitation and a considerable period of sick leave has to be considered. These factors may have influenced results in favour of the ESWT group. After this study, Peers et al concluded that ESWT is a good alternative to surgical treatment when conservative treatment fails in chronic patellar tendinopathy.

In 2003 Peers wrote a thesis about the effectiveness of ESWT in Achilles and patellar tendinopathy. In a randomised clinical trial he compared focused ESWT treatment, consisting of three sessions with an energy level of 0.2 mJ/mm², with a placebo treatment (three sessions with an energy level of 0.03 mJ/mm²). The study group consisted of 21 patients; the control group included 20 patients. Evaluation after 12 weeks was performed using VISA score, R&M classification and degree of functional impairment. There was a significant improvement in pain and function after ESWT treatment of 0.2 mJ/mm². Another evaluation variable was the VAS score, but for this variable no significant difference was found. In this study the follow-up lasted only 3 months, so no conclusion could be drawn for the long-term benefit. Another limitation of this study was that no limits were set on the severity of patellar tendinopathy at inclusion, so patients with mild or severe complaints were both included in this study. One might argue...
<table>
<thead>
<tr>
<th>Author</th>
<th>Publication year</th>
<th>Study design</th>
<th>Outcome measures</th>
<th>Follow-up period in months</th>
<th>Number of patients (total/ study group)</th>
<th>Duration of symptoms in months</th>
<th>Severity before ESWT</th>
<th>Previous treatment before ESWT</th>
<th>ESWT type</th>
<th>Energy level (mJ/mm²)</th>
<th>Energy level (mJ/mm²)</th>
<th>Number of treatments</th>
<th>Additional treatment after ESWT</th>
<th>Mean VAS and VISA after ESWT (improvement)</th>
<th>Improved patients (%)</th>
<th>Significant differences in advantage of ESWT treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Varà F et al</td>
<td>2000 Abstract</td>
<td>Randomised clinical trial, single-blind</td>
<td>VAS score, pressure pain, functional improvement</td>
<td>24</td>
<td>27/14, all athletes</td>
<td>&gt;6</td>
<td>VAS 1.6</td>
<td>Two of the following treatments: NSAIDs, physical therapy, steroid injections, patellar bracing, acupuncture or immobilisation</td>
<td>Dolorclast Siemens Sonocur</td>
<td>0.105–0.437 (medium)</td>
<td>0.06–0.18 (low-medium)</td>
<td>24</td>
<td>None</td>
<td>VAS 0.3* (13.1) VISA 83.9</td>
<td>74% (11/14) improved, good and satisfactory</td>
<td>Yes</td>
</tr>
<tr>
<td>Lohrer H et al</td>
<td>2002</td>
<td>Non-randomised, prospective pilot study</td>
<td>Pain at rest, pain during exercise and pressure pain (all VAS scores), and pain-free running time (min)</td>
<td>12</td>
<td>45/45, all athletes</td>
<td>13.9</td>
<td>VAS 5.5 (pressure pain), VAS 5.5 (during exercise), pain-free running time 10.4 min</td>
<td>Siemens Sonocur Focused</td>
<td>0.08 (medium)</td>
<td>3 (1000 imp)</td>
<td>3</td>
<td>None</td>
<td>VAS 1</td>
<td>64.4% (29/45) improved, pain-free or less pain</td>
<td>Yes</td>
<td>64.4% (29/45) improved, pain-free or less pain</td>
</tr>
<tr>
<td>Peers KHE et al</td>
<td>2003</td>
<td>Retrospective cross-sectional analysis</td>
<td>VISA score, VAS score and R&amp;Mc classification</td>
<td>24</td>
<td>27/14 (28/15 tendons), all athletes</td>
<td>3</td>
<td>VAS 5</td>
<td>Two of the following treatments: NSAIDs, physical therapy or steroid injections</td>
<td>Sonocur Plus Siemens Focused</td>
<td>0.2 (medium)</td>
<td>3 (1000 imp)</td>
<td>3</td>
<td>None</td>
<td>VISA 1</td>
<td>66% (10/15) improved, excellent and good</td>
<td>Yes</td>
</tr>
<tr>
<td>Peers KHE</td>
<td>2003</td>
<td>Randomised clinical trial</td>
<td>VISA score, VAS score, R&amp;Mc classification and functional improvement</td>
<td>3</td>
<td>41/21, all athletes</td>
<td>&gt;3</td>
<td>VISA 6.0</td>
<td>NSAIDs, physical therapy, steroid injections or patellar taping</td>
<td>Siemens Sonocur Focused</td>
<td>0.17 (medium)</td>
<td>3–5 (2000 imp)</td>
<td>3</td>
<td>None</td>
<td>VISA 46.5</td>
<td>61.9% (13/21) improved, less pain, function improved</td>
<td>Yes</td>
</tr>
<tr>
<td>Taunton KM et al</td>
<td>2003</td>
<td>Randomised clinical trial</td>
<td>VISA score and vertical jump test</td>
<td>3</td>
<td>20/10, all athletes</td>
<td>&gt;=3</td>
<td>VISA 92.0* (44.43)</td>
<td>Steroid injections NSAIDs or physiotherapy</td>
<td>OssaeTen Siemens Sonocur STORZ</td>
<td>0.18 (medium)</td>
<td>1 (1500 imp)</td>
<td>3</td>
<td>None</td>
<td>VISA 6.0</td>
<td>70% (7/10) improved, less pain, function improved</td>
<td>Yes</td>
</tr>
<tr>
<td>Wang CJ et al</td>
<td>2007</td>
<td>Randomised clinical trial</td>
<td>VISA score, VAS score, R&amp;Mc classification, functional improvement and echo image of patellar tendon</td>
<td>36</td>
<td>50/27 (54/30 tendons), all athletes</td>
<td>&gt;=3</td>
<td>VISA 7.1</td>
<td>NSAIDs, physical therapy, steroid injections or patellar taping</td>
<td>Siemens Sonocur STORZ</td>
<td>0.08–0.44 (low-high)</td>
<td>3–5 (1500–2500 imp)</td>
<td>3</td>
<td>None</td>
<td>VISA 42.57</td>
<td>90.1% (27/30) improved, excellent and good</td>
<td>Yes</td>
</tr>
<tr>
<td>Vulpiani MC et al</td>
<td>2007</td>
<td>Non-randomised, prospective cohort study</td>
<td>VAS score, subjective clinical evaluation range</td>
<td>&gt;24</td>
<td>73/73 (83/83 tendons), 15 athletes</td>
<td>&gt;=3</td>
<td>VISA 92.0* (44.43)</td>
<td>NSAIDs, physical therapy, steroid injections or patellar taping</td>
<td>Siemens Sonocur STORZ</td>
<td>0.08–0.44 (low-high)</td>
<td>3–5 (1500–2500 imp)</td>
<td>3</td>
<td>None</td>
<td>VISA 7.10</td>
<td>79.9% (66/83) improved and satisfied</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Table 2** Summary of studies on ESWT and patellar tendinopathy

**Author**
- Varà F et al
- Lohrer H et al
- Peers KHE et al
- Peers KHE
- Taunton KM et al
- Wang CJ et al
- Vulpiani MC et al

**Publication year**
- 2000
- 2002
- 2003
- 2003
- 2003
- 2007
- 2007

**Study design**
- Randomised clinical trial, single-blind
- Non-randomised, prospective pilot study
- Retrospective cross-sectional analysis
- Randomised clinical trial
- Randomised clinical trial
- Randomised clinical trial
- Non-randomised, prospective cohort study

**Outcome measures**
- VAS score, pressure pain, functional improvement
- Pain at rest, pain during exercise and pressure pain (all VAS scores), and pain-free running time (min)
- VISA score, VAS score and R&M classification
- VISA score, VAS score, R&M classification and functional improvement
- VISA score and vertical jump test
- VISA score, VAS score, R&M classification, functional improvement and echo image of patellar tendon

**Follow-up period in months**
- 24
- 12
- 24
- 3
- 3
- 36
- 24

**Number of patients (total/ study group)**
- 27/14
- 45/45, all athletes
- 27/14 (28/15 tendons), all athletes
- 41/21, all athletes
- 20/10, all athletes
- 50/27 (54/30 tendons), all athletes
- 73/73 (83/83 tendons), 15 athletes

**Duration of symptoms in months**
- >6
- 13.9
- >3
- 23
- >3
- 16.2
- >3

**Severity before ESWT**
- VAS 1.6
- VAS 5.5 (pressure pain), VAS 5.5 (during exercise), pain-free running time 10.4 min
- VAS 5
- VISA 46.5
- VISA 54.4
- VISA 6.0
- VISA 42.57

**Previous treatment before ESWT**
- Two of the following treatments: NSAIDs, physical therapy, steroid injections, patellar bracing, acupuncture or immobilisation
- Two of the following treatments: NSAIDs, physical therapy or steroid injections
- NSAIDs, physical therapy, steroid injections or patellar taping
- NSAIDs
- NSAIDs
- Steroid injections
- NSAIDs or physiotherapy

**ESWT type**
- Dolorclast Siemens Sonocur
- Sonocur Plus Siemens Sonocur
- Siemens Sonocur
- OssaeTen
- Siemens Sonocur
- STORZ
- Medica Focused

**Energy level (mJ/mm²)**
- 0.105–0.437 (medium)
- 0.06–0.18 (low-medium)
- 0.08 (medium)
- 0.2 (medium)
- 0.17 (medium)
- 0.18 (medium)
- 0.08–0.44 (low-high)

**Number of treatments**
- 1–5
- 3–5 (2000 imp)
- 3–5 (1000 imp)
- 3 (1000 imp)
- 3–5 (2000 imp)
- 1 (1500 imp)
- 3–5 (1500–2500 imp)

**Local anaesthetic**
- none
- none
- none
- none
- none
- none
- none

**Method of localisation**
- patient-guided feedback
- image guiding
- image guiding
- none
- palpaton, control by imaging
- none
- none

**Additional treatment after ESWT**
- none
- Eccentric training, single leg decline squat
- none
- none
- palpaton, control by imaging
- none
- none

**Mean VAS and VISA after ESWT (improvement)**
- VAS 0.3* (13.1)
- VISA 1
- VISA 3 (2.0)
- VISA 61.4* (7.0)
- VISA 54.4
- VISA 54.4
- VISA 54.4

**Improved patients (%)**
- 74% (11/14) improved, good and satisfactory
- 66% (10/15) improved, excellent and good
- 61.9% (13/21) improved, less pain, function improved
- 70% (7/10) improved, less pain, function improved
- 90.1% (27/30) improved, excellent and good
- 79.9% (66/83) improved and satisfied
- 70% (7/10) improved, less pain, function improved

**Significant differences in advantage of ESWT treatment**
- Yes
- Yes
- Yes, except for VAS score and R&M classification
- Yes, except for diameter and appearance of patellar tendon
- Yes
- Yes
- Yes

**Delphi score**
- 3
- 3
- 7
- 4
- 6
- 2
ESWT seems to be encouraging in light of the long-lasting improvement of the pain symptomatology. ESWT was more effective and safer than conservative treatment in patients with chronic patellar tendinopathy.

Table 2

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Abstract</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vara F et al</td>
<td>2000</td>
<td>Abstract</td>
<td>ESWT positively contributed to the improvement of pain and function in the short-term treatment of patellar tendinopathy.</td>
</tr>
<tr>
<td>Peers KHE et al</td>
<td>2002</td>
<td>RCT</td>
<td>ESWT does have a therapeutic effect on patellar tendinopathy.</td>
</tr>
<tr>
<td>Taunton KM et al</td>
<td>2003</td>
<td>RCT</td>
<td>ESWT treatment is a good alternative for surgical interventions and other conservative treatments, like eccentric training.</td>
</tr>
<tr>
<td>Wang CJ et al</td>
<td>2007</td>
<td>RCT</td>
<td>ESWT does have a therapeutic effect on chronic patellar tendinopathy.</td>
</tr>
<tr>
<td>Vulpiani MC et al</td>
<td>2007</td>
<td>RCT</td>
<td>ESWT positively contributed to the improvement of pain and function in the short-term treatment of patellar tendinopathy.</td>
</tr>
<tr>
<td>Taunton KM et al</td>
<td>2007</td>
<td>RCT</td>
<td>ESWT treatment is a good alternative for surgical interventions and other conservative treatments, like eccentric training.</td>
</tr>
<tr>
<td>Peers KHE et al</td>
<td>2008</td>
<td>RCT</td>
<td>ESWT does have a therapeutic effect on patellar tendinopathy.</td>
</tr>
</tbody>
</table>

For Delphi score see figure 2.23

Figure 2 Delphi score

<table>
<thead>
<tr>
<th>Delphi score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Treatment allocation</td>
</tr>
<tr>
<td>a. Was a method of randomisation performed? Yes/No/Don’t know</td>
</tr>
<tr>
<td>b. Was the treatment allocation concealed? Yes/No/Don’t know</td>
</tr>
<tr>
<td>2. Were the groups similar at baseline regarding the most important prognostic indicators? Yes/No/Don’t know</td>
</tr>
<tr>
<td>3. Were the eligibility criteria specified? Yes/No/Don’t know</td>
</tr>
<tr>
<td>4. Was the outcome assessor blinded? Yes/No/Don’t know</td>
</tr>
<tr>
<td>5. Was the patient blinded? Yes/No/Don’t know</td>
</tr>
<tr>
<td>6. Was the care provider blinded? Yes/No/Don’t know</td>
</tr>
<tr>
<td>7. Were point estimates and measures of variability presented for the primary outcome measures? Yes/No/Don’t know</td>
</tr>
<tr>
<td>8. Did the analysis include an intention-to-treat analysis? Yes/No/Don’t know</td>
</tr>
</tbody>
</table>

That patients with only mild complaints had a better prognosis and consequently influenced the results positively, but, because a strict randomisation was applied, patients with only mild complaints were found in both groups. Peers concluded that ESWT positively contributed to improvement of pain and function in the short-term treatment of patellar tendinopathy.26

In 2003 Taunton et al evaluated the effects of ESWT for patellar tendinopathy. In a randomised clinical trial, 10 patients in the study group received from three to five focused ESWT treatments with an energy level of 0.17 mJ/mm². In the control group, 10 patients underwent the same treatment procedure but with an absorbing pad between skin and probe, so only a placebo treatment was given. Evaluation up to 12 weeks after the last treatment included a questionnaire, VISA score and a vertical jump test. The VISA score and vertical jump test improved significantly in the study group. A limitation of this study was that no VAS score was used for the evaluation, even though it is a useful indicator of pain relief. Also in this study a short follow-up time was used and the number of patients was only 20. Taunton et al concluded that ESWT treatment could be of value as an additional treatment to other conservative therapies, like eccentric training.27

Wang et al (2007) evaluated the efficiency and safety of ESWT treatment for patellar tendinopathy. In a randomised controlled trial they compared one focused ESWT treatment of 0.18 mJ/mm² with the results of conservative treatment. This study consisted of 27 patients (30 tendons) in the study group and 23 patients (24 tendons) in the control group. After 1, 3, 6, 12, 24 and 36 months VISA and VAS scores, functional improvement and ultrasonographic examination of the patellar tendon were evaluated. There was a significant improvement in patients who had been treated with ESWT. They showed functional improvement and both the VAS and the VISA scores improved. Ultrasonographic examination revealed a significant increase in vascularisation. There were no serious side effects or complications. According to Wang et al, this study had some limitations. The number of patients was small and the length of follow-up was relatively short, although the length of follow-up of this study was the largest of all seven studies included. The functional improvement of the knee was assessed subjectively on the performance of daily activities, including sports participation. Despite these limitations, they concluded that ESWT was more effective and safer than conservative treatment for patients with chronic patellar tendinopathy.23

In 2007 Vulpiani et al reported a prospective study on the treatment of jumper’s knee using ESWT. All included patients had a confirmed jumper’s knee for at least 3 months, with pain not responding to previous conservative treatment. All 73
patients (83 tendons) received from three to five focused ESWT treatments with an energy level of 0.08–0.44 mJ/mm². Already 1 month after ESWT treatment a significant improvement in the average VAS score was found, and the VAS scale improved further during follow-up. Additional evaluations after 1 month and in short-term (6–12 months), medium-term (13–24 months) and long-term (>24 months) periods showed satisfactory results in respectively 43%, 64%, 69% and 80% of the patients. However, 14 tendons were lost to follow-up. Clear limitations in this study were the study design, without a control group, and the impossibility of achieving a 100% patient recall. The study of Vulpiani et al showed positive effects of ESWT treatment for patellar tendinopathy, so they concluded that the results were encouraging in light of the long-lasting improvement of the pain symptomatology.14

DISCUSSION

All of the seven studies included in this review concluded that ESWT seems to be an effective treatment for patellar tendinopathy. It is a safe treatment as well because no serious side effects have been reported. Since there are many differences in the treatment protocols used, it would be inappropriate to attempt a quantitative meta-analysis on the effectiveness of ESWT for patellar tendinopathy, but based on these studies it can be estimated that in approximately 74.7% of patients ESWT treatment resulted in improvement of pain and knee function. The results should be interpreted with caution, though, since the quality of the studies is variable (Delphi score ranged from 2 to 7 out of a maximum of 9).15 Three studies16 17 18 were non-randomised, two studies had no control group,19 20 and one study had a retrospective design.6 Of the RCTs, one study compared ESWT treatment with conservative treatment,21 while in others placebo ESWT was applied to the control group.22 23 24 One RCT was only single-blinded.24 Patients were blinded in only two studies. Further, in most studies small numbers of patients were used and the post-treatment follow-up time was generally short.5 13 14 24–27 Because of the aforementioned limitations, which are also indicated by the fact that there were only two satisfactory Delphi scores, it is hard to draw firm conclusions about the effectiveness of ESWT for patellar tendinopathy.

Since no appropriate conservative or surgical treatments for this common injury have been described so far, we believe that the mainly positive results from these studies justify further research into the role that ESWT can play in the management of athletes with patellar tendinopathy. Double-blind, randomised controlled studies in larger patient groups and with sufficient follow-up time, for at least 3 years, using standardised treatment protocols are necessary to assess the true value of ESWT for patellar tendinopathy. Based on the available evidence in the literature it is impossible to recommend a specific ESWT treatment protocol. Hence comparative studies between different treatment strategies are also urgently needed. In this way, important questions with regard to number and frequency of treatments, energy level and method of shockwave application will be answered. There is no consensus either about the use of anaesthetics; it seems that their use is unnecessary. Almost all patients in this review received ESWT therapy without anaesthetics and they all tolerated it well.

Research in the field of ESWT and tendinopathies is still hampered by the fact that both the pathophysiology of patellar tendinopathy and the exact working mechanism of ESWT have not been elucidated so far. The underlying pathology in patellar tendinopathy is considered to be a failed healing response due to a degenerative process resulting from excessive overload5 15 16 21 25 27–30 rather than a prostaglandin-mediated inflammatory process5 16. Neovascularisation is often found in patellar tendinopathy, and it has been hypothesised that tendon pain is caused by sensory nerves that grow into the tendon, causing a neurogenic inflammation and pain response.30 A further explanation of the pain in patellar tendinopathy could be the disturbance of nociceptive transmission in the nervous system, by means of changed levels of substance P (SP), glutamate and tyrosine hydroxylase (TH).30 Little is known about the working mechanism of ESWT. In animal studies it has been demonstrated that ESWT may have an impact on the nociceptive transmission in the nervous system and that it can cause dysfunction of peripheral, sensory nerve fibres, resulting in pain relief.30 ESWT probably has an influence on neovascularisation as well. Surprisingly, Wang et al found, along with the clinical improvement of their patients, a significant increase of vascularisation after ESWT treatment.15 They supposed the increased vascularity led to better tissue regeneration in tendinopathies through a better blood supply.15 This finding is in flat contradiction to the aforementioned theory about neurovascular structures and pain. A possible explanation could be that, due to the improvement in pain and function, patients became more active, resulting in increased vascularity.31 In athletes the degree of neovascularisation can also vary during the season,32 but no data on sport participation were given by Wang. In order to develop an effective ESWT treatment protocol for patellar tendinopathy it is crucial to elucidate the exact pathophysiology of patellar tendinopathy and to clarify the working mechanism of shockwaves on (pathological) tendon tissue and neovascularisation. Without more basic knowledge of these phenomena, ESWT will remain a controversial treatment.

So far, ESWT has mainly been used to treat patients with a chronic severe patellar tendinopathy not responsive to other conservative treatments. The mean VISA score of the patients of the included studies was 47.8. In more than 50% of those studies, the mean duration of symptoms was over 6 months.
and patients had mostly had several other treatments already. This may have negatively influenced the outcome of the studies. We believe that ESWT could be of help in an earlier, less severe stage of the disease as well. ESWT can potentially play a role in the management of tendon pain and therefore should be incorporated into a more comprehensive exercise-based rehabilitation programme. A more comprehensive programme also seems justified when we look at the VISA scores after treatment. Healthy athletes have a VISA score of around 95 points. In these studies the maximum VISA score was 92 and the average VISA score was 78. Peers et al showed that results of ESWT therapy equal the results of surgical treatment for patellar tendinopathy; results showed a VISA score of respectively 83 and 70. Bahr et al compared surgical treatment with eccentric training; results showed a VISA score of 70 for both groups. ES   WT treatment seems just as effective as, or even more effective than, existing treatments for patellar tendinopathy, but a completely normal knee function is probably not feasible with monotherapy. A more comprehensive exercise-based rehabilitation programme could therefore help to achieve higher VISA scores.

In conclusion, ESWT seems to be a safe and promising treatment for patellar tendinopathy. Because ESWT treatment seems to have a positive effect on pain and function, it could be part of a rehabilitation programme for this chronic overuse injury. However, based on the current knowledge it is impossible to recommend a specific treatment protocol. Further basic and clinical research into the working mechanism and effectiveness of ESWT for patellar tendinopathy is necessary.

Competing interests: None.

REFERENCES

Extracorporeal shockwave therapy for patellar tendinopathy: a review of the literature

M T van Leeuwen, J Zwerver and I van den Akker-Scheek

doi: 10.1136/bjsm.2008.050740

Updated information and services can be found at:
http://bjsm.bmj.com/content/43/3/163.1

These include:

References
This article cites 28 articles, 4 of which you can access for free at:
http://bjsm.bmj.com/content/43/3/163.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/